Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Christine E. Swenson"'
Autor:
Arthur C. Louie, Andrew S. Janoff, Christine E. Swenson, Lawrence D. Mayer, Stephen K.L. Chia, Wilson H. Miller, Kim N. Chi, Karen A. Gelmon, Gerald Batist
Supplementary Data from Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a7b50adbb285907a5434afd58b6d58a
https://doi.org/10.1158/1078-0432.22440048.v1
https://doi.org/10.1158/1078-0432.22440048.v1
Autor:
Arthur C. Louie, Andrew S. Janoff, Christine E. Swenson, Lawrence D. Mayer, Stephen K.L. Chia, Wilson H. Miller, Kim N. Chi, Karen A. Gelmon, Gerald Batist
Purpose: CPX-1 is a novel, liposome-encapsulated formulation of irinotecan and floxuridine designed to prolong in vitro optimized synergistic molar ratios of both drugs postinfusion. This open-label, single-arm, dose-escalating phase I study was desi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36db2a19fd23f88a2e9ead6ed1ec7c8e
https://doi.org/10.1158/1078-0432.c.6517425.v1
https://doi.org/10.1158/1078-0432.c.6517425.v1
Autor:
Christine E Swenson, Dieter Haemmerich, Donald H Maul, Bridget Knox, Nicole Ehrhart, Robert A Reed
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0139752 (2015)
Radiofrequency ablation (RFA) is used for the local treatment of liver cancer. RFA is effective for small ( 3 cm, there is a tendency to leave viable tumor cells in the margins or clefts of overlapping ablation zones. This increases the possibility o
Externí odkaz:
https://doaj.org/article/2d44424fa18a44698acf7b48801d0df3
Autor:
Christine E. Swenson, Lawrence D. Mayer, Alan F. List, Steven L. Allen, Jeffrey E. Lancet, Arthur C. Louie, Eric J. Feldman, Ekatherine Asatiani, Ellen K. Ritchie, Jonathan E. Kolitz, Gail J. Roboz
Publikováno v:
Journal of Clinical Oncology. 29:979-985
Purpose This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351. Patients and Methods CPX-351 induction was administered on days 1, 3, and 5 by 90-minute infu
Publikováno v:
Journal of Pharmaceutical Sciences. 98:2540-2548
CPX-351 (cytarabine/daunorubicin liposome injection) is a liposomal formulation of a synergistic, fixed combination of the antineoplastic drugs cytarabine and daunorubicin for intravenous infusion. The two drugs are contained within the liposome in a
Autor:
Rachel Stevens, Andrew S. Janoff, Christine E. Swenson, David A. Stevens, Patricia Roberts, Imran Ahmad, Walter Perkins
Publikováno v:
Antimicrobial Agents and Chemotherapy. 42:767-771
Amphotericin B lipid complex for injection (ABLC) is a suspension of amphotericin B complexed with the lipids l -α-dimyristoylphosphatidylcholine (DMPC) and l -α-dimyristoylphosphatidylglycerol. ABLC is less toxic than amphotericin B deoxycholate (
Autor:
Stephane DeWit, Elias Anaissie, Gary Horwith, Alejandro Llanos-Cuentas, Christine E. Swenson, Anthony Boyle, Jean-Paul Sculier, José F. Bernardo, Lois E. Bolsack, Robert A. Branch, E. Kelly, D. DeValeriola, J. Klasterksy, Adedayo Adedoyin, Gabriel Lopez-Berestein
Publikováno v:
Scopus-Elsevier
Amphotericin B (AmB) has been the most effective systemic antifungal agent, but its use is limited by the dose-limiting toxicity of the conventional micellar dispersion formulation (Fungizone). New formulations with better and improved safety profile
Publikováno v:
Antimicrobial Agents and Chemotherapy. 41:886-892
Amphotericin B lipid complex (ABLC) shows reduced toxicity relative to that of amphotericin B deoxycholate (AmB-d) while maintaining antifungal activity. Rat blood or plasma was spiked with ABLC in vitro. Released amphotericin B was separated from th
Publikováno v:
Journal of Liposome Research. 3:451-471
Despite its associated toxicities, amphotericin B remains the drug of first choice for a variety of systemic fungal infections that were invariably fatal prior to its introduction. A natural product of Streptomyces, the structure of this compound is
Autor:
Robert F. Pasternack, Andrew S. Janoff, Walter Perkins, Sharma R. Minchey, Mircea C. Popescu, Christine E. Swenson, Lawrence T. Boni
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Biomembranes. 1107:271-282
When interacting with phospholipid in an aqueous environment, amphotericin B forms unusual structures of markedly reduced toxicity (Janoff et al. (1988) Proc. Natl. Acad. Sci. USA 85, 6122-6126). These structures, which appear ribbon-like by freeze-f